CD163 versus CD68 in tumor associated macrophages of classical hodgkin lymphoma

Diagnostic Pathology

Volumn 7, Issue 1, 2012, Pages

  Harris, Jonathan A ^a   Jain, Salvia ^a   Ren, Qinghu ^a   Zarineh, Alirezah ^a   Liu, Cynthia ^a   Ibrahim, Sherif ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD163 ANTIGEN; CD68 ANTIGEN, HUMAN; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; DISEASE FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MACROPHAGE; MALE; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; TIME; UNITED STATES;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; DISEASE-FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MALE; MIDDLE AGED; NEW YORK CITY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, CELL SURFACE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84862777574     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-7-12     Document Type: Article

References (11)

1. Bjorkholm M, et al. Fixed versus response-adapted MOPP/ABVD chemotherapy in Hodgkin's disease. A prospective randomized trial. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 1995, 6(9):895-9.
2. Steidl C, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. The New England journal of medicine 2010, 362(10):875-85. 10.1056/NEJMoa0905680, 2897174, 20220182.
3. Alvaro-Naranjo T, et al. Tumor-infiltrating cells as a prognostic factor in Hodgkin's lymphoma: a quantitative tissue microarray study in a large retrospective cohort of 267 patients. Leukemia & lymphoma 2005, 46(11):1581-91. 10.1080/10428190500220654, 22299028.
4. Alvaro T, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clinical cancer research: an official journal of the American Association for Cancer Research 2005, 11(4):1467-73.
5. Sanchez-Aguilera A, et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood 2006, 108(2):662-8. 10.1182/blood-2005-12-5125, 16551964.
6. Devilard E, et al. Gene expression profiling defines molecular subtypes of classical Hodgkin's disease. Oncogene 2002, 21(19):3095-102. 10.1038/sj.onc.1205418, 12082542.
7. Chetaille B, et al. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood 2009, 113(12):2765-3775. 10.1182/blood-2008-07-168096, 19096012.
8. Chen JJ, et al. Tumor-associated macrophages: the double-edged sword in cancer progression. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2005, 23(5):953-64.
9. Fonseca JE, et al. Macrophage subpopulations in rheumatoid synovium: reduced CD163 expression in CD4+ T lymphocyte-rich microenvironments. Arthritis and rheumatism 2002, 46(5):1210-6. 10.1002/art.10207, 12115225.
10. Nguyen TT, et al. Expression of CD163 (hemoglobin scavenger receptor) in normal tissues, lymphomas, carcinomas, and sarcomas is largely restricted to the monocyte/macrophage lineage. The American journal of surgical pathology 2005, 29(5):617-24. 10.1097/01.pas.0000157940.80538.ec, 15832085.
11. Azambuja D, et al. Lack of association of tumor associated macrophages with clinical outcome in patients with classical Hogkin's lymphoma. Annals of oncology 2011,